The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

Eli Lilly (NYSE:LLY) has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

Glaswegian cosmetic practitioner Awfa Paulina said weight-loss drugs can be 'effective tools', but that no guarantees can be ...

Eli Lilly’s request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief the outcome could affect its business and that the FDA does not adequately represent its ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

Scots nurse Susan McGowan died after just two low doses of a weight-loss jab. Susan, 58, took medical advice before using ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies to produce Victoza, also known as liraglutide, following a proposal by the ...

Can Ozempic and similar drugs cause muscle and bone loss? Discover how to maintain your health while achieving weight loss ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.